KR

Krishnakumar Ramanlal Parikh

Active Director Director DIN 01177215
DIN 01177215 First appointment Feb 2002 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 4 active board seats
Past companies 1 historical roles
Total affiliations 5 Since Feb 2002
Shareholding value •••• Premium profile

About Krishnakumar Ramanlal Parikh

Data last updated:

Krishnakumar Ramanlal Parikh is a Director at Choksi Asia Limited (since 2024), Director at Choksi Asia Limited (since 2024) and Director at Manodaya Trading Private Limited (since 2019), and holds 1 more current directorship. The companies operate in Healthcare, Financial Services and Chemicals. The 4 current companies with reported revenue have a combined latest revenue of ₹7.70 Cr; the largest is Choksi Asia Limited at ₹3.61 Cr (FY 2022). Earlier, Krishnakumar Ramanlal Parikh was a Director at Medical Solutions (India) Private Limited (2009–2010).

DIN 01177215
Primary Designation Director
Industry Healthcare
First Appointment 25 Feb 2002
Oldest Company Age 34 yrs
Largest company Choksi Asia Limited · ₹3.61 Cr (FY 2022)
Combined revenue ₹7.70 Cr across 4 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Choksi Asia Limited L71200MH1992PLC388063
Director01 Sep 20241992₹3.61 Cr (FY 2022)Active
Choksi Asia Limited L71200DN1992PLC005901
Director01 Sep 20241992₹3.61 Cr (FY 2022)Active
Manodaya Trading Private Limited U67120MH1992PTC067285
Director01 Mar 20191992₹44.4 Lakh (FY 2025)Active
Mahavishnu Drugs Private Limited U24100MH1997PTC108188
Director25 Feb 20021997₹4.1 Lakh (FY 2017)Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director19 Oct 20092001₹44.1 Lakh (FY 2025)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Mahavishnu Drugs Private Limited
Manodaya Trading Private Limited
Choksi Asia Limited
Choksi Asia Limited
Premium access

Shareholding and investment profile for Krishnakumar Ramanlal Parikh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Krishnakumar Ramanlal Parikh

Krishnakumar Ramanlal Parikh currently holds 4 directorships: Choksi Asia Limited (Director, since 01 Sep 2024, revenue ₹3.61 Cr (FY 2022)); Choksi Asia Limited (Director, since 01 Sep 2024, revenue ₹3.61 Cr (FY 2022)); Manodaya Trading Private Limited (Director, since 01 Mar 2019, revenue ₹44.4 Lakh (FY 2025)); Mahavishnu Drugs Private Limited (Director, since 25 Feb 2002, revenue ₹4.1 Lakh (FY 2017)).

Krishnakumar Ramanlal Parikh was first appointed on 25 Feb 2002 as Director at Mahavishnu Drugs Private Limited. The most recent appointment on record is 01 Sep 2024 at Choksi Asia Limited.

The 4 current companies of Krishnakumar Ramanlal Parikh that report revenue have a combined latest revenue of ₹7.70 Cr: Choksi Asia Limited ₹3.61 Cr (FY 2022); Choksi Asia Limited ₹3.61 Cr (FY 2022); Manodaya Trading Private Limited ₹44.4 Lakh (FY 2025); Mahavishnu Drugs Private Limited ₹4.1 Lakh (FY 2017).

Krishnakumar Ramanlal Parikh held 1 earlier board appointment: Medical Solutions (India) Private Limited (Director, 19 Oct 2009 to 26 Oct 2010).

The current boards of Krishnakumar Ramanlal Parikh's companies include Brijal Mitesh Desai (Choksi Asia Limited), Jay Samir Choksi (Choksi Asia Limited), Samir Kanubhai Choksi (Choksi Asia Limited), Shraddha Prajit Gandhi (Choksi Asia Limited), Tushar Madhuvandas Parikh (Choksi Asia Limited), Ashwini Mehta Rozal (Manodaya Trading Private Limited), among others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available